{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:45:35Z","timestamp":1791888335472,"version":"4.3.4"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA173453"],"award-info":[{"award-number":["CA173453"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Lung cancer is the second most common cancer in the United States, and small cell lung cancer (SCLC) accounts for about 15% of all lung cancers. In SCLC, more than other malignancies, the standard of care is based on clinical demonstration of efficacy, and less on a mechanistic understanding of why certain treatments work better than others. This is in large part due to the virulence of the disease, and lack of clinically or biologically relevant biomarkers beyond routine histopathology. While first line therapies work in the majority of patients with extensive stage disease, development of resistance is nearly universal. Although neuroendocrine features, Rb and p53 mutations are common, the current lack of actionable biomarkers has made it difficult to develop more effective treatments. Some progress has been made with the application of immune checkpoint inhibitors. There are new agents, such as lurbinectedin, that have completed late-phase clinical testing while other agents are still in the pre-clinical phase. ONC201\/TIC10 is an imipridone with strong <jats:italic>in vivo<\/jats:italic> and <jats:italic>in vitro<\/jats:italic> antitumor properties and activity against neuroendocrine tumors in phase 1 clinical testing. ONC201 activates the cellular integrated stress response and induces the TRAIL pro-apoptotic pathway. Combination treatment of lurbinectedin with ONC201 are currently being investigated in preclinical studies that may facilitate translation into clinical trials for SCLC patients.<\/jats:p>","DOI":"10.3389\/fphar.2021.747180","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T19:26:36Z","timestamp":1630697196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies"],"prefix":"10.3389","volume":"12","author":[{"given":"Nicholas R.","family":"Liguori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Azzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafik S.","family":"El-Deiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"74380","DOI":"10.18632\/oncotarget.11814","article-title":"Discovery and Clinical Introduction of First-In-Class Imipridone ONC201","volume":"7","author":"Allen","year":"2016","journal-title":"Oncotarget"},{"key":"B2","doi-asserted-by":"publisher","first-page":"171ra17","DOI":"10.1126\/scitranslmed.3004828","article-title":"Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects","volume":"5","author":"Allen","year":"2013","journal-title":"Sci. Transl Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-015-0346-9","article-title":"Identification of TRAIL-Inducing Compounds Highlights Small Molecule ONC201\/TIC10 as a Unique Anti-cancer Agent that Activates the TRAIL Pathway","volume":"14","author":"Allen","year":"2015","journal-title":"Mol. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/jco.2021.39.15_suppl.3002","article-title":"Phase 2 Study of DRD2 antagonist\/ClpP Agonist ONC201 in Neuroendocrine Tumors","volume":"39","author":"Anderson","year":"2021","journal-title":"Jco"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e16703","DOI":"10.1200\/jco.2020.38.15_suppl.e16703","article-title":"Phase II Study of ONC201 in Pheochromocytoma-Paragangliomas (PC-PG), Medullary Thyroid Carcinoma (MTC), and Other Neuroendocrine Tumors","volume":"38","author":"Anderson","year":"2020","journal-title":"Jco"},{"key":"B6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab Alone and Nivolumab Plus Ipilimumab in Recurrent Small-Cell Lung Cancer (CheckMate 032): a Multicentre, Open-Label, Phase 1\/2 Trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nrc821","article-title":"Targeting Death and Decoy Receptors of the Tumour-Necrosis Factor Superfamily","volume":"2","author":"Ashkenazi","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1097\/JTO.0b013e31822e2941","article-title":"A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer","volume":"6","author":"Baggstrom","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/cncr.30062","article-title":"Vismodegib or Cixutumumab in Combination with Standard Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E1508)","volume":"122","author":"Belani","year":"2016","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-3-319-40389-2_14","article-title":"Small Cell Lung Cancer","volume-title":"Lung Cancer: Treatment and Research","author":"Bernhardt","year":"2016"},{"key":"B11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccell.2017.01.013","article-title":"Awakening of \"Schlafen11\" to Tackle Chemotherapy Resistance in SCLC","volume":"31","author":"Berns","year":"2017","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000244","article-title":"Mechanisms of Action for Different Checkpoint Inhibitors","volume":"3","author":"Berraondo","year":"2019","journal-title":"HemaSphere"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1080\/15384101.2017.1339849","article-title":"Family Matters: How MYC Family Oncogenes Impact Small Cell Lung Cancer","volume":"16","author":"Br\u00e4gelmann","year":"2017","journal-title":"Cell Cycle"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1183\/09031936.00014009","article-title":"Pathogenesis of Lung Cancer Signalling Pathways: Roadmap for Therapies","volume":"33","author":"Brambilla","year":"2009","journal-title":"Eur. Respir. J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ccr.2013.05.005","article-title":"Small Molecule Inhibitors of aurora-a Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma","volume":"24","author":"Brockmann","year":"2013","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000464278","article-title":"Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report","volume":"10","author":"Brzezniak","year":"2017","journal-title":"Case Rep. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/cncr.29098","article-title":"Small Cell Lung Cancer: where Do We Go from Here?","volume":"121","author":"Byers","year":"2015","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1200\/jco.2018.36.15_suppl.8507","article-title":"Efficacy and Safety of Rovalpituzumab Tesirine in Patients with DLL3-Expressing, \u2265 3rd Line Small Cell Lung Cancer: Results from the Phase 2 TRINITY Study","volume":"36","author":"Carbone","year":"2018","journal-title":"Jco"},{"key":"B19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/s0360-3016(97)00094-1","article-title":"Superior Vena Cava Obstruction in Small-Cell Lung Cancer","volume":"38","author":"Chan","year":"1997","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/hmg\/ddq529","article-title":"Notch Inhibition by the Ligand DELTA-LIKE 3 Defines the Mechanism of Abnormal Vertebral Segmentation in Spondylocostal Dysostosis","volume":"20","author":"Chapman","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"768","DOI":"10.21037\/tlcr-19-547","article-title":"Mechanisms of Drugs-Resistance in Small Cell Lung Cancer: DNA-Related, RNA-Related, Apoptosis-Related, Drug Accumulation and Metabolism Procedure","volume":"9","author":"Chen","year":"2020","journal-title":"Transl Lung Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/jco.2018.36.15_suppl.8506","article-title":"Phase 2 Study of Pembrolizumab in Advanced Small-Cell Lung Cancer (SCLC): KEYNOTE-158","volume":"36","author":"Chung","year":"2018","journal-title":"Jco"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.molmed.2017.10.002","article-title":"Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective","volume":"23","author":"Cifaldi","year":"2017","journal-title":"Trends Mol. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","article-title":"Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1\/2 Mutations and Selected Sporadic Cancers","volume":"7","author":"de Bono","year":"2017","journal-title":"Cancer Discov."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092522","article-title":"Immunotherapy in Small Cell Lung Cancer","volume":"12","author":"Esposito","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1084\/jem.190.8.1155","article-title":"Human Dendritic Cells Mediate Cellular Apoptosis via Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)","volume":"190","author":"Fanger","year":"1999","journal-title":"J. Exp. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0162133","DOI":"10.1371\/journal.pone.0162133","article-title":"Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study","volume":"11","author":"Feng","year":"2016","journal-title":"PLOS ONE"},{"key":"B28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.bbagrm.2014.03.005","article-title":"Small-molecule Inhibitors of the Myc Oncoprotein","volume":"1849","author":"Fletcher","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1128\/mcb.16.9.4604","article-title":"Activation of Vascular Endothelial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1","volume":"16","author":"Forsythe","year":"1996","journal-title":"Mol. Cel Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11864-018-0568-3","article-title":"Targeted Therapy and Immune Therapy for Small Cell Lung Cancer","volume":"19","author":"Gadgeel","year":"2018","journal-title":"Curr. Treat. Options. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nrc.2017.106","article-title":"Small-cell Lung Cancer: what We Know, what We Need to Know and the Path Forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive Genomic Profiles of Small Cell Lung Cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-med-081313-121208","article-title":"The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy","volume":"66","author":"Goldstein","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing Epidemiology of Small-Cell Lung Cancer in the United States over the Last 30 years: Analysis of the Surveillance, Epidemiologic, and End Results Database","volume":"24","author":"Govindan","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1084\/jem.189.8.1343","article-title":"Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor-Related Cytokine, TRAIL","volume":"189","author":"Griffith","year":"1999","journal-title":"J. Exp. Med."},{"key":"B37","first-page":"727","article-title":"PD-1\/PD-L1 Pathway: Current Researches in Cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"6933","DOI":"10.1073\/pnas.94.13.6933","article-title":"Loss of the Retinoblastoma Protein-Related P130 Protein in Small Cell Lung Carcinoma","volume":"94","author":"Helin","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jtho.2019.01.028","article-title":"Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death","volume":"14","author":"Hsu","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-18-1040","article-title":"Metabolic Reprogramming by Dual AKT\/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma","volume":"24","author":"Ishida","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13046-016-0359-2","article-title":"Yin Yang 1 Is Associated with Cancer Stem Cell Transcription Factors (SOX2, OCT4, BMI1) and Clinical Implication","volume":"35","author":"Kaufhold","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"ra18","DOI":"10.1126\/scisignal.aac4374","article-title":"ONC201 Kills Solid Tumor Cells by Triggering an Integrated Stress Response Dependent on ATF4 Activation by Specific eIF2\u03b1 Kinases","volume":"9","author":"Kline","year":"2016","journal-title":"Sci. Signal."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1128\/mcb.8.8.3373","article-title":"Multiple Mechanisms for Transcriptional Regulation of the Myc Gene Family in Small-Cell Lung Cancer","volume":"8","author":"Krystal","year":"1988","journal-title":"Mol. Cel Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.lungcan.2014.05.003","article-title":"Randomized Phase II Study of Carboplatin and Etoposide with or without Obatoclax Mesylate in Extensive-Stage Small Cell Lung Cancer","volume":"85","author":"Langer","year":"2014","journal-title":"Lung Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/sj.bjc.6605950","article-title":"Bcl-2 and \u03b21-integrin Predict Survival in a Tissue Microarray of Small Cell Lung Cancer","volume":"103","author":"Lawson","year":"2010","journal-title":"Br. J. Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1158\/1538-7445.am2020-5260","article-title":"Abstract 5260: Preclinical Studies with ONC201 in Combination with Clinically Approved Chemotherapy as a Novel Treatment Strategy against Small Cell Lung Cancer (SCLC)","volume":"80","author":"Lee","year":"2020","journal-title":"Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1158\/0008-5472.CAN-18-0161","article-title":"NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model","volume":"78","author":"Liu","year":"2018","journal-title":"Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/sj.leu.2404317","article-title":"Aberrant Stabilization of C-Myc Protein in Some Lymphoblastic Leukemias","volume":"20","author":"Malempati","year":"2006","journal-title":"Leukemia"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s40265-020-01374-0","article-title":"Lurbinectedin: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B51","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/onco.13752","article-title":"FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer","volume":"26","author":"Mathieu","year":"2021","journal-title":"Oncologist"},{"key":"B52","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/bjc.1990.232","article-title":"The Role of Glutathione in Resistance to Cisplatin in a Human Small Cell Lung Cancer Cell Line","volume":"62","author":"Meijer","year":"1990","journal-title":"Br. J. Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.4049\/jimmunol.1401114","article-title":"Dopamine Inhibits the Effector Functions of Activated NK Cells via the Upregulation of the D5 Receptor","volume":"193","author":"Mikulak","year":"2014","journal-title":"J. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","article-title":"MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition","volume":"31","author":"Mollaoglu","year":"2017","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"45266","DOI":"10.1038\/srep45266","article-title":"The Histone Deacetylase Inhibitor Valproic Acid Inhibits NKG2D Expression in Natural Killer Cells through Suppression of STAT3 and HDAC3","volume":"7","author":"Ni","year":"2017","journal-title":"Sci. Rep."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/JCO.20.02212","article-title":"Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451","volume":"39","author":"Owonikoko","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/nm.2473","article-title":"A Crucial Requirement for Hedgehog Signaling in Small Cell Lung Cancer","volume":"17","author":"Park","year":"2011","journal-title":"Nat. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s40425-019-0690-1","article-title":"Immunotherapy in Small-Cell Lung Cancer: from Molecular Promises to Clinical Challenges","volume":"7","author":"Pavan","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-14-2958","article-title":"Small Cell Lung Cancer: Will Recent Progress lead to Improved Outcomes?","volume":"21","author":"Pietanza","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, Double-Blind, Phase II Study of Temozolomide in Combination with Either Veliparib or Placebo in Patients with Relapsed-Sensitive or Refractory Small-Cell Lung Cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.neo.2020.09.005","article-title":"ONC201 and Imipridones: Anti-cancer Compounds with Clinical Efficacy","volume":"22","author":"Prabhu","year":"2020","journal-title":"Neoplasia"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1158\/1535-7163.MCT-17-0121","article-title":"ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-triple-negative Breast Cancers through TRAIL-dependent and TRAIL-independent Mechanisms","volume":"16","author":"Ralff","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study","volume":"38","author":"Rudin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3389\/fonc.2020.01074","article-title":"Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)","volume":"10","author":"Saltos","year":"2020","journal-title":"Front. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.1016\/j.lungcan.2004.07.967","article-title":"Treatment of Brain Metastases from Lung Cancer: Chemotherapy","author":"Schuette","year":"2004","journal-title":"Lung Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/0008-5472.CAN-16-3409","article-title":"CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib","volume":"77","author":"Sen","year":"2017","journal-title":"Cancer Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/9511","article-title":"Extracellular Matrix Proteins Protect Small Cell Lung Cancer Cells against Apoptosis: A Mechanism for Small Cell Lung Cancer Growth and Drug Resistance In Vivo","volume":"5","author":"Sethi","year":"1999","journal-title":"Nat. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1200\/JCO.2002.02.108","article-title":"Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Marimastat after Response to First-Line Chemotherapy in Patients with Small-Cell Lung Cancer: a Trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer","volume":"20","author":"Shepherd","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.devcel.2005.07.014","article-title":"The Cdk1 Complex Plays a Prime Role in Regulating N-Myc Phosphorylation and Turnover in Neural Precursors","volume":"9","author":"Sjostrom","year":"2005","journal-title":"Dev. Cel"},{"key":"B72","first-page":"545","article-title":"HDAC Inhibitors Suppressed Small Cell Lung Cancer Cell Growth and Enhanced the Suppressive Effects of Receptor-Targeting Cytotoxins via Upregulating Somatostatin Receptor II","volume":"10","author":"Sun","year":"2018","journal-title":"Am. J. Transl Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as Second-Line Treatment for Patients with Small-Cell Lung Cancer: a Single-Arm, Open-Label, Phase 2 Basket Trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1172\/JCI96711","article-title":"Dose Intensification of TRAIL-Inducing ONC201 Inhibits Metastasis and Promotes Intratumoral NK Cell Recruitment","volume":"128","author":"Wagner","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.7150\/jca.27780","article-title":"The Prospective Value of Dopamine Receptors on Bio-Behavior of Tumor","volume":"10","author":"Wang","year":"2019","journal-title":"J. Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1001\/archinte.141.11.1499","article-title":"Treatment of Small Cell Lung Cancer - 1981","volume":"141","author":"Weisenthal","year":"1981","journal-title":"Arch. Intern. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/science.6274023","article-title":"Specific Chromosome Defect Associated with Human Small-Cell Lung Cancer; Deletion 3p(14-23)","volume":"215","author":"Whang-Peng","year":"1982","journal-title":"Science"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s0093-7754(01)90072-7","article-title":"Molecular Genetics of Small Cell Lung Carcinoma","volume":"28","author":"Wistuba","year":"2001","journal-title":"Semin. Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3978\/j.issn.2072-1439.2013.07.04","article-title":"The Development of Targeted Therapy in Small Cell Lung Cancer","volume":"5","author":"Zhang","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.neo.2021.06.007","article-title":"EZH2i EPZ-6438 and HDACi Vorinostat Synergize with ONC201\/TIC10 to Activate Integrated Stress Response, DR5, Reduce H3K27 Methylation, ClpX and Promote Apoptosis of Multiple Tumor Types Including DIPG","volume":"23","author":"Zhang","year":"2021","journal-title":"Neoplasia"},{"key":"B81","doi-asserted-by":"crossref","DOI":"10.1101\/2020.10.20.347633","volume-title":"HIF1\u03b1 Inhibition by Dual Targeting of CDK4\/6 and HSP90 Reduces Cancer Cell Viability Including Rb-Deficient Cells","author":"Zhao","year":"2020"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e65860","DOI":"10.1371\/journal.pone.0065860","article-title":"Dopamine Receptors Modulate Cytotoxicity of Natural Killer Cells via cAMP-PKA-CREB Signaling Pathway","volume":"8","author":"Zhao","year":"2013","journal-title":"PLoS One"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e2015748","DOI":"10.1001\/jamanetworkopen.2020.15748","article-title":"Comparison of First-Line Treatments for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis","volume":"3","author":"Zhou","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1158\/0008-5472.CAN-20-2808","article-title":"Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis","volume":"81","author":"Zhu","year":"2021","journal-title":"Cancer Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s11095-013-1231-0","article-title":"The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells","volume":"32","author":"Zhu","year":"2015","journal-title":"Pharm. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.747180\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T19:26:42Z","timestamp":1630697202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.747180\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":85,"alternative-id":["10.3389\/fphar.2021.747180"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.747180","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"article-number":"747180"}}